TVS Motor Company Creates a ‘New Freestyle Performance’ Segment with the Global Launch of Its All New Naked Sports TVS Apache RTR 310
Backed by a rich racing pedigree spanning over four decades, TVS Motor Company unveils the latest addition and a new flagship to its iconic Apache line-up: the TVS Apache RTR 310. This highly anticipated naked sports motorcycle is set to redefine the realm of two-wheeled exhilaration with its impressive blend of power, agility and style and is poised to captivate motorcycle enthusiasts and adrenaline aficionados around the world. It promises an unmatched riding experience, setting new benchmarks and offering a gateway into the world of the freestyler.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230906303314/en/
Vimal Sumbly, Head Business - Premium, TVS Motor Company and Dr Bernhard Heiming, CTO, TVS Motor Company (Photo: Business Wire)
The TVS Apache RTR 310 leads in innovation right from its unique design, engine layout, heat management and many differentiated technologies which are focused on rider engagement, safety and comfort.
Speaking on the occasion, Mr. Sudarshan Venu, Managing Director, TVS Motor Company, said, "TVS Motor Company has always transformed and redefined technology with the TVS Apache series at the helm, where we brought to life tech led innovations such as ride modes, slipper clutch, connectivity, fully adjustable suspension and the Built to Order Platform. The global launch of the all the new TVS Apache RTR 310 marks a momentous occasion for us, as this motorcycle encapsulates Apache’s 18 year legacy of innovation and performance. With the TVS Apache RTR 310, we're taking our engineering to a whole new level, offering enthusiasts a motorcycle that's not only powerful but also brings together different technologies to give a unique riding experience. This motorcycle is positioned to be the flagship product for many global markets including India, Europe, LATAM and ASEAN."
Speaking at the launch, Vimal Sumbly, Head Business – Premium, TVS Motor Company, said, “The TVS Apache RTR 310 is the first of a new generation of Apache’s that inherit a 40 year racing pedigree and are based on our ‘Track to Road’ philosophy. This machine will be the start of a new era of Freestyle Performance Motorcycling with a core essence of thrill and fun. With many defining technologies, this flagship Apache like every other Apache will lead in technology setting new benchmarks for the category. Its cyborg inspired streetfighter design, all range torque and track tuned agility, elevates the fun of motorcycling for the new age riders – Power to Play for the Freestyler.
The TVS Apache RTR series is already established as a formidable force in the naked format amongst premium lifestyle segment, The TVS Apache series recently crossed its 5 million global sales milestone becoming the fastest growing premium motorcycle brand in the segment.”
Redefining Tech:
|
Segment First |
Segment Defining |
|
|
■ Cruise Control |
■ Bidirectional Quickshifter |
|
|
■ Dynamic Class D LED Headlamp |
■ Race Tuned Linear Stability Control |
|
|
■ Dynamic Brake Lamp |
■ Lightweight aluminum sub frame |
|
|
■ 5 Ride Modes including all new Supermoto Mode |
■ Tire Pressure Monitoring System |
|
|
■ Climatic Control Seats (Heating and Cooling) |
■ Unique Reverse Inclined DOHC Engine |
|
|
■ 5” TFT Cluster with GoPro Control, Music Control, Voice Assist, Smart Helmet Device Connectivity, Telephony and Navigation |
|
|
|
■ Race Tuned Dynamic Stability Control with 6D IMU
|
|
|
Variant |
Price (Ex-Showroom India) |
|
Arsenal Black (w/o Quickshifter) |
₹ 2,42,990 |
|
Arsenal Black |
₹ 2,57,990 |
|
Fury Yellow |
₹ 2,63,990 |
|
BTO (Built To Order) |
|
|
•Dynamic Kit |
₹ 18,000 |
|
•Dynamic Pro Kit |
₹ 22,000 |
|
•Sepang Blue |
₹ 10,000 |
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230906303314/en/
Contact information
Nikita Verma – nikita.verma@tvsmotor.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Axelspace: Notice of Signing a Service contract for In-Orbit Demonstration with Pale Blue, Inc.22.12.2025 11:00:00 EET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” has entered into a service agreement with Pale Blue Inc. (“Pale Blue”), a company that develops, manufactures, and sells thrusters (engines) for small satellites, for an in-orbit demonstration, as detailed below. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219321165/en/ Jun Asakawa, Co-founder & CEO of Pale Blue (left in photo) and Yuya Nakamura, President and CEO of Axelspace Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Under this contract, an in-orbit demonstration of a fast-start Hall thruster developed by Pale Blue is scheduled to be conducted in 2027. Nonetheless, conducting in-orbit demonstrations in a short period of time is known to be a significant challenge due to the in
Axelspace Signing Agreement on a Multi-Launch Arrangement and the Launch of New Satellites with Exolaunch22.12.2025 11:00:00 EET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” is pleased to announce a multi-launch agreement (MLA) with Exolaunch, a global launch integrator and leader in launch mission management, satellite integration and satellite deployment technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219038364/en/ The Multi-Launch Agreement will accelerate the growth of Axelspace. In particular, one satellite scheduled for launch under the new Agreement will be used in the AxelLiner business’s in-orbit demonstration service, “AxelLiner Laboratory”. Exolaunch has already secured launches for eight (8) Axelspace’s satellites on the upcoming missions. Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Nonetheless, conducting in-orbit demonstration
Zambon Biotech Announces First Patient Dosed in Phase 3b ADIP Clinical Study of IPX203 in Parkinson’s Disease22.12.2025 11:00:00 EET | Press release
Zambon Biotech, a specialized biotech company part of the Zambon group that aims to build a scientifically robust and commercially viable portfolio of innovative patient-oriented drugs through the scouting, acquisition, licensing and development of new molecules, today announced that the first participant with advanced Parkinson’s disease has been enrolled in the European Phase 3b ADIP (IPX203 in Advanced Parkinson’s disease) study, which is planned to evaluate the efficacy and safety of IPX203 versus immediate-release (IR) levodopa/carbidopa (LD/CD) in a regimen which has not yet been the focus of a Phase 3 trial. IPX203 is a novel, oral modified-release formulation of LD/CD designed for the treatment of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. IPX203 contains immediate-release granules and extended-release beads, providing both a rapid onset of action and a longer duration of benefit, sustaining the levo
Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 10:00:00 EET | Press release
Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity. Pimicotinib, a colony stimulating factor-1 receptor (CSF-1R) inhibitor developed by Abbisko Therapeutics Co., Ltd., Shanghai, China, is the first Chemical Drug Class 1 approved in China for the treatment of TGCT. “We are continuing to deliver on our commitment to improving the lives of patients with rare tumors with this first-in-the-world regulatory approval of pimicotinib,” said Danny Bar-Zohar, CEO Healthcare and Member of the Executive Board of Merck. “This approval is a significant step forward in further strengthening our leadership in rare tumors, while offering patients the opportunity to change the course of
Incyte Japan Announces Approval of Minjuvi ® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 09:44:00 EET | Press release
Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom